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Abstract
Hereditary spherocytosis (HS) patients have increased rates of erythropoiesis and higher folate 
requirements. In a case-control study in HS patients, we evaluated the associations between the 
use of 5 mg FA daily and serum concentrations of folate, unmetabolized folic acid (UMFA), 
interleukin (IL)-6, IL-8, IL-10, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α); and 
mRNA expression of dihydrofolate reductase (DHFR), methylene tetrahydrofolate reductase 
(MTHFR), IL8, IFNG and TNFA genes. Total serum folate and folate forms were measured in 27 
HS patients (21 users [HS-U] and 6 non-users [HS-NU] of supplemental FA) and 54 healthy 
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controls not consuming 5 mg/d supplemental FA. Each patient was matched to two controls based 
on age, sex and BMI. The mononuclear leukocyte mRNA expression of relevant genes and their 
products were determined. Serum folate, UMFA, 5-methyl-tetrahydrofolate (5-methyl-THF), and 
tetrahydrofolate (THF) concentrations were significantly higher in HS-U compared with matched 
healthy controls (P<0.001, n=42). HS-NU had lower serum folate concentrations than matched 
healthy controls (P=0.044, n=12). HS-U and HS-NU presented similar hematological and 
biochemical markers profiles. No differences were found between HS-U and HS-NU for cytokine 
serum concentrations and mRNA expression genes. DHFR mRNA expression was higher in HS-U 
than in HS-NU. The use of high daily doses of FA for treatment of HS patients may be excessive 
and is associated with elevated serum UMFA and elevated DHFR mRNA expression. It is not 
known whether long-term high dose folic acid use by HS patients might have adverse health 
effects.
Keywords
folic acid; unmetabolized folic acid; hereditary spherocytosis; DHFR; cytokines
INTRODUCTION
Hereditary spherocytosis (HS) is an inherited hemolytic anemia most prevalent in 
Caucasians, affecting around 1 in 2,000 individuals. The HS phenotype may arise from one 
of several mutations that lead to defects or deficiency in one or more proteins present in red 
blood cell (RBC) membranes, such as band 3, protein 4.2, ankyrin and β-spectrin.[1] As a 
result, RBCs lose small vesicles of cytoplasmic membrane containing lipids and proteins, 
reducing their membrane surface area, and leading to a spherical-shaped (spherocytes).[1] 
The abnormal shape leads to reduced deformability of the cells and consequent premature 
trapping and destruction by the spleen. Shortened red cell lifespan results in increased 
compensatory rates of red cell production.[2, 3]
To ensure adequate nutrient requirements for increased erythropoietic demands, folic acid 
(FA) is usually prescribed for patients with chronic hemolysis. However, guidelines are 
lacking regarding the optimal dose of FA.[1, 4]
FA is a synthetic form of folate that must be reduced by the enzyme dihydrofolate reductase 
(DHFR) to be incorporated into the active cellular pool of folate.[5] The activity of DHFR 
could be a limiting factor for FA reduction in people consuming greater than the Tolerable 
Upper Intake Level (UL) of 1 mg/day of the vitamin in the form of folic acid,[6] leading to 
the appearance of unmetabolized FA (UMFA) in the circulation. Although no definitive 
adverse outcomes have been linked to high FA intakes, a recent study carried out by our 
group showed that intake of 5 mg of FA daily for 3 months by healthy individuals reduced 
the number and the cytotoxic activity of natural killer (NK) cells and was associated with 
elevated mRNA expression of interleukin-8 (IL8) and tumor necrosis factor-α (TNFA) 
genes.[7]
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In Brazil, patients with HS and other chronic hemolytic states are being prescribed 5 mg of 
FA daily, which is 5 times higher than the UL for healthy individuals.[8] It is not known 
what the effects of this high FA dose are in chronically supplemented individuals.
Thus, the aims of this study were to assess whether there is an association between elevated 
UMFA and proinflammatory cytokinelevels when HS patients were treated long-term with 5 
mg of FA daily.
METHODS
Twenty-seven HS patients seen at hematology centers in the cities of Sao Paulo and 
Sorocaba (Brazil) were recruited for this study and 54 healthy people were recruited as a 
control group from the same community. Each patient was matched to two controls by age, 
sex and body mass index (BMI), the main covariates that may confound the analysis. 
Although patients were prescribed 5 mg of FA daily, six of them self-reported not taking FA 
during the interview conducted by our team. We took advantage of the fact that some 
patients were not using FA daily because of non-compliance with the treatment, which 
enabled us to compare HS patients who were users (HS-U) and non-users (HS-NU).
The Institutional Ethics Committee approved this study (CNS 466/12, CAEE 
04389512.2.000.0067), and a written informed consent was obtained from all subjects prior 
to their inclusion in the study. The analysis of blinded specimens by the CDC Nutritional 
Biomarkers Laboratory (serum folate forms) does not constitute engagement in human 
subject research. Other blood measurements were performed in laboratories at the University 
of Sao Paulo, Brazil.
The exclusion criteria were: age less than 18 years, chronic alcoholism, acute or chronic 
diseases, pregnancy, use of immunosuppressive drugs, and people who donated or received 
blood transfusion within 6 months of the study. Furthermore, control subjects who used FA, 
either in the form of multivitamins or vitamin-minerals mixtures in the last 6 months were 
also excluded from the study.
Venous blood samples were obtained by venipuncture from each participant after an 
overnight fast (8-10 hours). Serum folate was determined by a microbiologic assay with the 
use of Lactobacillus casei (chloramphenicol-resistant strain NCIB 10463) and FA (F7876 
Sigma Aldrich folic acid 98%) as calibrator.[9] Concentrations of serum folate forms 
[UMFA, tetrahydrofolate (THF), 5-methyl-THF, 5-formyl-THF, 5,10-methenyl-THF, and 
MeFox (an oxidation product of 5-methyl-THF)] were analyzed by high performance liquid 
chromatography-tandem MS (HPLC-MS/MS).[10] Serum total folate was calculated as the 
sum of these folate forms excluding MeFox. Plasma methylmalonic acid (MMA) was 
assessed by HPLC-MS/MS. Other biochemical analyses, as well as hematological, mRNA 
expression analysis and NK cell count, were performed as described previously.[7]
BMI was calculated by dividing weight (kg) by height2 (m) and the measures were 
performed as previously described.[11] Subjects were classified as underweight (BMI <18.5 
kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/m2) and 
obese (BMI ≥30.0 kg/m2).[12]
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Dietary intake assessment
Dietary intake was assessed by two 24-hour dietary recalls (24-HR) in each period of the 
study, the first one on the day of blood collection and the second one a few days after blood 
collection, as previously described.[7, 11]
Statistical analyses
Statistical analyses were carried out using SPSS version 22.0 (IBM, USA) and GraphPad 
Prism™ version 5.04 (GraphPad Software, Inc., USA) software.
Serum folate concentration <7.0 nmol/L was defined as folate deficiency.[13] The value of 
45 nmol/L (20 ng/mL) for serum folate was considered as a cutoff due to being the upper 
limit of the assay calibration curve in many serum folate assays. Elevated serum UMFA was 
defined as a serum concentration >1.98 nmol/L, according to the 95th percentile in the 
distribution of values obtained for fasted persons in the NHANES 2007-2008 survey.[14]
Elevated plasma total homocysteine (tHcy) was defined as a plasma concentration >13.9 
μmol/L.[15] Vitamin B12 deficiency was defined as a serum B12 concentration <256 
pmol/L, while functional vitamin B12 deficiency was defined as a B12 concentration <256 
pmol/L and MMA >271 nmol/L.[16] Anemia was defined as a hemoglobin concentration 
<120 g/L for women and <130 g/L for men.[17]
HS disease severity was classified adapting the criteria previously described,[18] by using 
values of hemoglobin (Hb), reticulocyte count (Ret) and serum total bilirubin (TBi). Thus, 
HS patients were stratified as Trait: Hb normal, Ret <3% and TBi <17 μmol/L; Mild: Hb 
110-150 g/L, Ret 3-6 % and TBi 17-34 μmol/L; Moderate: Hb 80-120 g/L, Ret 6-10% and 
TBi 34-51 μmol/L; Severe: Hb 60-80 g/L, Ret >10% and TBi >51 μmol/L. To be accepted in 
a category the patient needed at least two parameters compatible with the classification. 
When the three parameters (Hb, Ret and TBi) were not enough to establish the disease 
staging, Hb was used as the arbiter criterion for classification.
The chi-square test, or the likelihood ratio and Fisher’s exact tests were used to analyze the 
frequencies of categorical variables. The Mann-Whitney test was used to compare numeric 
variables between groups.
Spearman correlations between serum UMFA and serum cytokine concentrations and among 
serum cytokine concentrations were performed in each group studied.
In order to define a cutoff for serum folate that represents a higher likelihood of having 
elevated UMFA concentrations, the area under the ROC curve was obtained for UMFA 
>1.98 nmol/L as a dependent variable and serum folate concentration measured by HPLC-
tandem mass spectrometry as an independent variable. The selected cutoff maximized 
sensitivity and specificity.
The level of significance was set at α = 5%, P ≤0.05.
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RESULTS
Among the 27 HS patients enrolled in this study, 21 were users of 5 mg FA daily (HS-U), 
while 6 were nonusers (HS-NU). Regarding BMI, only 1 woman in HS-U, 1 woman in HS-
NU and their respective controls were classified as obese. The characteristics of the HS 
patients and control subjects are shown in Table 1.
Natural food folate intake, folic acid intake and total food folate intake, expressed as dietary 
folate equivalents (DFEs), did not differ significantly among HS-U, HS-NU and their 
controls (Table 2).
Serum folate, UMFA, 5-methyl-THF, THF, and MeFox concentrations were significantly 
higher in HS-U compared with their controls (P <0.001) (Table 2). On the other hand, HS-
NU patients had lower serum folate concentrations (P = 0.044) and did not show differences 
regarding UMFA, 5-methyl-THF, THF and MeFox concentrations compared with their 
controls (Table 2). In addition, HS-U had higher serum folate, UMFA, and 5-methyl-THF 
than HS-NU patients (Figure 1).
In HS-U patients, serum UMFA represented on average 11.4% of total folate (HPLC-MS/
MS), while it represented on average 2.44% in their controls, 3.97% in HS-NU patients, and 
2.23% in HS-NU controls. The contribution of 5-methyl-THF to serum total folate (HPLC-
MS/MS) ranged from 63.3% in HS-U to more than 90% in HS-NU and both control groups.
No difference was found between HS-U or HS-NU patients and their controls concerning 
serum vitamin B12 and tHcy concentration (P >0.050). However, MMA concentration was 
higher in HS-U patients than in their healthy controls (P=0.003). Vitamin B12 deficiency 
was observed in 23.8% of HS-U patients, but the deficiency frequency was similar to their 
healthy controls. Even when functional deficiency of vitamin B12 was observed, there was 
no difference between HS-U and their healthy controls (Table 2).
We found no significant difference between HS-U and HS-NU patients for any of the 
hematological or biochemical parameters, including the inflammation markers (Table 3). HS 
patients (users or non-users of 5 mg of FA daily) presented lower RBC counts and 
hemoglobin concentration, and higher values of reticulocytes and serum lactate 
dehydrogenase activity when compared with their controls (Table 3). Most HS-U and HS-
NU patients were anemic (76.2% and 83.3%, respectively) compared with only 3 (5.9%) 
healthy control subjects. Only HS-U patients had higher WBC and NK cell counts than their 
healthy controls (Table 3). When HS-U patients were classified according to the severity of 
clinical presentation of the disease (trait, mild, moderate or severe), no significant 
differences in NK cell counts were observed.
Higher concentrations of IL-8 and TNF-α were found in HS-U patients compared with their 
healthy controls (P <0.001), while HS-NU patients presented higher TNF-α concentrations 
(P = 0.028) but similar IL-8 concentrations compared with their healthy controls (Table 3). 
No differences were observed between HS patients and their controls regarding serum 
concentrations of IL-6, IL-10, interferon-γ (IFN- γ) and high sensitivity C-reactive protein 
(Hs-CRP) (P >0.05) (Table 3).
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We found no correlation between the serum cytokine concentrations with serum UMFA in 
54 controls (Table 4). However, there were inverse and moderate correlations (close to 
significance) between UMFA and IL-10 (rho= −0.400, P=0.072), and UMFA and IFN-γ 
(rho= −0.396, P=0.076) (Table 4).
Higher DHFR mRNA expression was found in HS-U compared with HS-NU patients. No 
differences were found between the two groups for MTHFR, IFNG, TNFA and IL8 mRNA 
expression genes (Figure 2).
The inflammatory biomarkers and mRNA expression evaluated in this study did not show 
significant differences when HS patients were classified according to the severity of their 
clinical presentation.
The cutoff for serum folate obtained by ROC analysis was 54 nmol/L (sensitivity=100% and 
specificity=91.7%) and the area under the curve (AUC) was 0.982 (CI 95%: 0.957-1.000), 
P<0.001.
DISCUSSION
To our knowledge, this is the first study that evaluated serum folate forms and inflammatory 
markers in HS patients receiving high doses of FA, exceeding the UL (1 mg/d). Our findings 
show that daily use of 5 mg of FA among HS patients resulted in unusually high serum 
folate concentrations and its non-metabolized form UMFA compared with healthy controls 
not consuming supplemental FA. Furthermore, a high proportion of elevated UMFA 
concentrations was found in HS-U patients when compared with their controls. The data that 
we obtained on patients not using folate was fortuitous and a result of patient noncompliance 
and the inclusion of six HS patients not using FA supplementation made it possible for us to 
assess the same biochemical markers when only one variable changed compared with the 
control group (i.e., disease status), albeit in a small group. We observed lower serum folate 
concentrations in HS-NU when compared with their healthy controls, confirming that HS 
patients require an additional supply of FA. However, 5 mg of FA daily may be an excessive 
dose and it may be more prudent to substantially reduce the daily dose. Titration of the ideal 
safe dose would require further studies to ensure adequacy of folate intake through 
monitoring of homocysteine or others metabolite status.
The appropriate FA dose is a subject of discussion for hemolytic anemias, including HS, 
especially according to disease severity. A few studies have described different doses, 
ranging from 1 mg/day, 2.5 mg/day, 5 mg once a week, and even 100 μg/kg/day.[4, 19, 20] 
The FA dose recommended by the Brazilian government for women in the periconceptional 
period is 5 mg daily,[21] and this dose has also been used for patients requiring higher 
amounts of FA due to HS or other hemolytic anemia over their entire lives.
In a previous study, we demonstrated that the daily use of 5 mg of FA by healthy individuals 
over 90 days, in a non-controlled intervention, led to increased UMFA concentrations, 
increased mRNA expression of the DHFR gene and of the cytokine IL8 and TNFA genes, 
and reduced number and cytotoxicity of NK cells.[7] The present study confirmed the 
increased mRNA expression of the DHFR gene. We hypothesize that the enzyme may be 
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upregulated due to saturation in the presence of excess FA. However, the present study did 
not find higher IL8 or TNFA mRNA gene expression in HS-U compared to HS-NU patients, 
possibly due to limited sample size. The much higher serum IL-8 and TNF-α concentrations 
in the two HS groups suggest that this may be a result of the disease (HS) and not from the 
use of FA. To our knowledge, this is the first study that showed the inflammatory cytokine 
profile, including IL-6, IL-8, IL-10, IFN-γ and TNF-α, in HS patients chronically subjected 
to high concentrations of FA. In the present study, NK cell counts in HS-U patients were 
higher than in healthy controls. This contrasts with our previous finding in which the NK 
counts decreased in healthy volunteers after they consumed 5mg FA daily for 90 days.[7] 
Unfortunately, we were not able to study sequential changes in WBC and NK number and 
activity in HS patients before and following initiation of FA supplementation, nor were we 
able to determine NK cell cytotoxicity in HS patients in the present study.
While we found no differences in serum vitamin B12 concentrations and functional 
deficiency of this vitamin between HS-U patients or HS-NU patients and their respective 
controls, HS-U patients had higher MMA concentrations than their controls. On the other 
hand, concentrations of tHcy were similar between HS groups and their controls. This 
observation raises the possibility that high concentrations of folate caused by intake of 
supplemental FA may negatively affect B12 status, as has been noted in other reports 
[22-24].
The serum folate concentration that is associated with elevated UMFA concentrations (>1.98 
nmol/L) is not yet known. We found that a serum folate cutoff of >54 nmol/L showed a high 
sensitivity and specificity for predicting elevated UMFA concentrations >1.98 nmol/L. This 
cutoff is close to 45 nmol/L, suggested previously as a high folate cutoff [13], and could be 
used to distinguish between individuals with normal compared with elevated UMFA, since 
UMFA determination is not easily available due to high cost.
The major limitation of our study is the relatively small number of HS patients, which is due 
to the low prevalence of this disease in our region. However, we highlight as strengths of this 
study the assessment of hematological and inflammatory cytokine profiles of patients with 
hemolytic anemia with low-grade inflammation using chronically high amounts of FA.
From this case-control study, we conclude that daily doses of 5 mg of FA, for treatment of 
HS patients was associated with elevated serum folate forms and elevated DHFR mRNA 
expression. We were not able to show an effect of UMFA excess on modulation of immune 
response in HS patients. More studies with a larger number of patients are needed to verify 
possible health effects associated with the long-term use of high FA doses, which exceed the 
UL in patients with chronic hemolytic anemias. This may be particularly relevant in 
individuals with functional asplenia or post-surgical splenectomy such as might occur in 
sickle cell disease or HS, who are already more susceptible to infections, particularly those 
caused by unicellular parasitic infections.
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Summary box
What is already known about this subject:
• Hereditary spherocytosis (HS) patients present with chronic anemia and 
require greater amounts of folate for maintaining adequate erythropoiesis.
• Most of these patients receive 5 mg/day of folic acid, a synthetic molecule 
that needs to be reduced to tetrahydrofolate by the enzyme DHFR before it 
can be be incorporated into the active cellular pool of folate.
• This high dose of folic acid (5-fold the Tolerable Upper Intake Level of folic 
acid for healthy subjects), and part of this folic acid circulates in blood as 
unmetabolized form.
• There are concerns about the risk of such high concentration, especially in 
relation to unmetabolized folic acid (UMFA).
What are the new findings:
• In our study we demonstrate, high concentrations of unmetabolized folic acid 
(UMFA) and total serum folate in HS patients.
• To our knowledge, this is the first time UMFA was determined in HS patients. 
In a previous study by us, we demonstrated high folic acid could affect NK 
cell activity.
• We demonstrate higher DHFR mRNA expression in HS patients using 5 
mg/day of folic acid compared with HS patient that are not using folic acid.
• We performed a hematologic and inflammatory profile in HS patients.
How might it impact on clinical practice in the foreseeable future?
• Differently than previously thought, excess folic acid is not completely 
eliminated in the urine and persistently high circulating concentrations can be 
observed in these patients.
• We believe that the doses of folic acid used routinely in HS patients need to 
be reduced to minimize potential health risks.
• Since determination of UMFA is not available in routine laboratories, 
determination of total serum folate may be useful for monitoring therapy in 
these patients. Thus, we propose an upper limit showing high sensitivity, and 
specificity cutoff for serum folate concentration that is associated with 
elevated UMFA concentrations.
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Figure 1. 
Concentrations of folate forms in patients with hereditary spherocytosis who are users (HS-
U) and non-users (HS-NU) of 5 mg of folic acid daily and healthy controls of the HS-U (C1) 
and HS-NU (C2) groups. (A) serum folate determined by microbiological assay; (B, C, D, 
E) serum folate, unmetabolized folic acid, 5-methyltetrahydrofolate and tetrahydrofolate, 
respectively, were determined by HPLC-tandem mass spectrometry. Mann-Whitney test was 
performed to compare the two groups. Patient above dashed horizontal line in C panel 
presented increased unmetabolized folic acid (cutoff point of 1.98 nmol/L).[14]
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Figure 2. 
mRNA expression of (A) Dihydrofolate reductase (DHFR), (B) Methylenetetrahydrofolate 
reductase (MTHFR), (C) Interferon-gamma (IFNG), (D) Tumor necrosis factor-α (TNFA), 
and (E) Interleukin-8 (IL-8) genes in hereditary spherocytosis patients who are users (HS-U) 
and non-users (HS-NU) of 5 mg of folic acid daily. Geometric mean values and 95% 
confidence intervals were shown.
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